44.24

0.11% -0.05

Disc Medicine Inc (IRON)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Disc Medicine Inc stock is traded at $44.24, with a volume of 345.67K. It is down -0.11% in the last 24 hours and up +14.32% over the past month. Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.

Previous Close:

$44.29

Open:

$44.35

24h Volume:

345.67K

Relative Volume:

0.83

Market Cap:

$1.71B

Revenue:

Net Income/Loss:

$-91.00M

P/E Ratio:

-12.05

EPS:

-3.67

Net Cash Flow:

$-74.38M

1W Performance:

-10.64%

1M Performance:

+14.32%

6M Performance:

-31.94%

1Y Performance:

+43.78%

1-Day Range:

$43.32

$45.57

1-Week Range:

$40.36

$50.40

52-Week Range:

$29.48

$68.73

Disc Medicine Inc Stock (IRON) Company Profile

Name

Disc Medicine Inc

Sector

Healthcare (1153)

Industry

Biotechnology (676)

Phone

(617) 674-9274

Address

321 ARSENAL STREET, SUITE 101, WATERTOWN

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

IRON's Discussions on Twitter

Compare IRON with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IRON Disc Medicine Inc	44.24	1.71B	0	-91.00M	-74.38M	-3.67
VRTX Vertex Pharmaceuticals Inc	424.99	128.84B	11.10B	-988.90M	-1.26B	-3.92
REGN Regeneron Pharmaceuticals Inc	527.78	65.38B	14.09B	4.50B	2.96B	39.28
ARGX Argen X Se Adr	549.65	39.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	251.15	33.82B	2.35B	-269.70M	-75.39M	-2.09
ONC Beigene Ltd Adr	231.99	27.60B	3.81B	-644.79M	-669.77M	-6.24

Disc Medicine Inc Stock (IRON) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-25	Initiated	TD Cowen	Buy
Nov-05-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Nov-04-24	Upgrade	Raymond James	Outperform → Strong Buy
Oct-23-24	Initiated	Jefferies	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-22-24	Initiated	Wells Fargo	Overweight
Apr-01-24	Downgrade	Raymond James	Strong Buy → Outperform
Dec-19-23	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-09-23	Upgrade	Raymond James	Outperform → Strong Buy
Jun-07-23	Initiated	H.C. Wainwright	Buy
May-17-23	Initiated	Raymond James	Outperform
Apr-28-23	Initiated	Cantor Fitzgerald	Overweight
Apr-21-23	Initiated	Stifel	Buy
Apr-20-23	Initiated	Morgan Stanley	Overweight
Mar-23-23	Initiated	BMO Capital Markets	Outperform
Feb-28-23	Initiated	SVB Securities	Outperform

View All

Disc Medicine Inc Stock (IRON) Latest News

02:10 AM

Wedbush Issues Negative Forecast for Disc Medicine Earnings - Defense World

02:10 AM

May 09, 2025

Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Recommendation of “Buy” by Analysts - Defense World

May 09, 2025

Disc Medicine Reports Strong Q1 2025 Progress - TipRanks

May 09, 2025

May 08, 2025

Here's Why We're Not Too Worried About Disc Medicine's (NASDAQ:IRON) Cash Burn Situation - Yahoo Finance

May 08, 2025

Decoding Disc Medicine Inc (IRON): A Strategic SWOT Insight - GuruFocus

May 08, 2025

May 07, 2025

Market Resilience: Disc Medicine Inc (IRON) Finishes Weak at 42.58, Down -12.40 - DWinneX

May 07, 2025

Disc Medicine Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 07, 2025

Disc Medicine reports Q1 EPS ($1.02), consensus ($1.07) - TipRanks

May 07, 2025

Disc Medicine, Inc. SEC 10-Q Report - TradingView

May 07, 2025